Second Affiliated Hospital

Company snapshot

Second Affiliated Hospital is a pharma organization headquartered in CN. Primary therapeutic focus areas include Immunotherapy, Opioid Analgesic Adverse Reaction, Liver Cancer, Ulcerative Colitis (UC). NovaPharmaNews links 4 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, and USPTO sources. Pipeline phase mix: phase 2 (2), approved (1).

• 4 active pipeline program(s) linked via ClinicalTrials.gov.
• 4 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Second Affiliated Hospital. Not investment advice.

Recent activity

Latest pipeline, patent, and corporate events for Second Affiliated Hospital.

1. Jun 8, 2026 Clinical update

   ZZ-IT-ICI-HCC 1line-023 — Phase 2

2. Jun 8, 2026 Clinical update

   Esketamine, Sulfentanil or/and Remifentanil — Unknown

3. Jun 8, 2026 Clinical update

   Cadonilimab — Phase 2

4. May 26, 2026 Clinical update

   Vedolizumab — Approved

View all clinical trial activity →

• What is Second Affiliated Hospital?

  Second Affiliated Hospital is a pharma organization headquartered in CN. Primary therapeutic focus areas include Immunotherapy, Opioid Analgesic Adverse Reaction, Liver Cancer, Ulcerative Colitis (UC). NovaPharmaNews links 4 clinical program(s), 0 drug profile(s), and 0 patent re

• Is Second Affiliated Hospital publicly traded?

  Second Affiliated Hospital appears in our database through regulatory marketing authorisation or clinical trial sponsor records; a US listed ticker is not shown for this entity.

• What drugs does Second Affiliated Hospital develop or market?

  We link 11 drug profile(s) where Second Affiliated Hospital is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/second-affiliated-hospital-of-soochow-university#company-drugs.

• What are the latest developments for Second Affiliated Hospital?

  In the last 12 months our linked public records show 4 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Second Affiliated Hospital focus on?

  Second Affiliated Hospital focuses on Immunotherapy, Opioid Analgesic Adverse Reaction, Liver Cancer based on our analysis of their pipeline programs and drug development activities.